♥
ISIN : INE700A01033
NSE : JUBLPHARMA
BSE : 530019
Face Value : 1
Industry : Pharmaceuticals & Drugs
EPS : 4.86
EPS (TTM) : 37.33
Price to Earning (P/E) : 184.34
Book Value : 343.00
Price to Bookvalue (P/B) : 2.61
Dividend Yield : 1 %
Return on Equity (ROE) : 1.34 %
Return on Capital Employed (ROCE) : 5.02 %
Jubilant Pharmova Limited
ISIN : INE700A01033
NSE : JUBLPHARMA
BSE : 530019
Face Value : 1
Industry : Pharmaceuticals & Drugs
EPS : 4.86
EPS (TTM) : 37.33
Price to Earning (P/E) : 184.34
Book Value : 343.00
Price to Bookvalue (P/B) : 2.61
Dividend Yield : 1 %
Return on Equity (ROE) : 1.34 %
Return on Capital Employed (ROCE) : 5.02 %
Jubilant Pharmova share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 820 - 839.75 2.4 % |
| Low / High | 800 - 842.75 5.3 % |
| Trade Volume | 5,011 |
| 52 Week Low / High | 783.75 - 1250 59.5 % |
-
YOU MAY ALSO LIKE
- Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - Share Market basics for beginners
Share Market jargons in simple terms - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Stock market course tutorial
Stock Market Investment Course explained in simple words.
CONSOLIDATED QUARTERLY RESULT FOR JUBILANT PHARMOVA LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 14517.2 | 15995 | 15525.1 | 16780 | 15869 | 16803 | 16771 | 17586 | 17317 | 17523 |
| Total Income | 14630.3 | 16126 | 15619.8 | 16824.5 | 15955 | 16902 | 17129 | 17730 | 17457 | 17740 |
| Total Expenditure | 12593.2 | 13807.5 | 14066.3 | 14587.8 | 14173 | 14385 | 14591 | 14872 | 14802 | 14629 |
| Other Income | 113.1 | 131 | 94.7 | 44.5 | 86 | 99 | 358 | 144 | 140 | 217 |
| Operating Profit | 2037.1 | 2318.5 | 1553.5 | 2236.7 | 1782 | 2517 | 2538 | 2858 | 2655 | 3111 |
| Interest | 399.3 | 420.2 | 506.9 | 555.6 | 619 | 661 | 713 | 730 | 710 | 610 |
| Exceptional Items | -568.2 | -1689 | 3959 | -142 | ||||||
| PBDT | 1637.8 | 1330.1 | 1046.6 | 1681.1 | 1163 | 1856 | 1825 | 439 | 5904 | 2359 |
| Depreciation | 945.7 | 939.5 | 942.8 | 2712.3 | 897 | 966 | 946 | 1010 | 907 | 914 |
| Profit Before Tax | 692.1 | 390.6 | 103.8 | -1031.2 | 266 | 890 | 879 | -571 | 4997 | 1445 |
| Tax | 223.1 | 314.8 | 247.7 | 141 | 192 | 359 | 346 | 81 | 179 | 419 |
| Profit After Tax | 469 | 75.8 | -143.9 | -1172.2 | 74 | 531 | 533 | -652 | 4818 | 1026 |
| Net Profit | 469 | 75.8 | -143.9 | -1172.2 | 74 | 531 | 533 | -652 | 4818 | 1026 |
| Equity Capital | 159.2 | 159.2 | 159.1 | 159.1 | 158 | 158 | 158 | 158 | 158 | 158 |
| Face Value (IN RS) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Calculated EPS | 2.95 | 0.34 | -0.98 | -6.15 | 0.41 | 3.96 | 4.23 | -3.71 | 30.51 | 6.51 |
| Diluted Eps After Extraordinary Items | 2.96 | 0.34 | -0.98 | -6.15 | 0.4 | 3.94 | 4.2 | -3.68 | 30.35 | 6.46 |
| Diluted Eps Before Extraordinary Items | 2.96 | 0.34 | -0.98 | -6.15 | 0.4 | 3.94 | 4.2 | -3.68 | 30.35 | 6.46 |
STANDALONE QUARTERLY RESULT FOR JUBILANT PHARMOVA LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 2045.7 | 2229.7 | 1827.4 | 1998.4 | 2174 | 1863 | 1752 | 2058 | 1667 | 1657 |
| Total Income | 2148.1 | 3290.9 | 1906.1 | 2135 | 2333 | 2047 | 1942 | 2559 | 1862 | 2095 |
| Total Expenditure | 2089.4 | 2156.7 | 1846.3 | 1976.6 | 2132 | 1855 | 1759 | 1936 | 1655 | 1718 |
| Other Income | 102.4 | 1061.2 | 78.7 | 136.6 | 159 | 184 | 190 | 501 | 195 | 438 |
| Operating Profit | 58.7 | 1134.2 | 59.8 | 158.4 | 201 | 192 | 183 | 623 | 207 | 377 |
| Interest | 31.5 | 41.4 | 55.3 | 57 | 64 | 71 | 83 | 81 | 76 | 78 |
| Exceptional Items | -112 | |||||||||
| PBDT | 27.2 | 1092.8 | 4.5 | 101.4 | 137 | 121 | 100 | 542 | 19 | 299 |
| Depreciation | 92.1 | 110.8 | 115.9 | 113.7 | 114 | 119 | 123 | 127 | 131 | 133 |
| Profit Before Tax | -64.9 | 982 | -111.4 | -12.3 | 23 | 2 | -23 | 415 | -112 | 166 |
| Tax | -13.1 | 63.9 | -52.5 | 296.3 | 4 | 6 | 1 | 90 | -10 | 61 |
| Profit After Tax | -51.8 | 918.1 | -58.9 | -308.6 | 19 | -4 | -24 | 325 | -102 | 105 |
| Net Profit | -51.8 | 918.1 | -58.9 | -308.6 | 19 | -4 | -24 | 325 | -102 | 105 |
| Equity Capital | 159.3 | 159.3 | 159.3 | 159.3 | 159 | 159 | 159 | 159 | 159 | 159 |
| Face Value (IN RS) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Calculated EPS | -0.33 | 5.76 | -0.37 | -1.94 | 0.12 | -0.03 | -0.15 | 2.04 | -0.64 | 0.66 |
| Diluted Eps After Extraordinary Items | -0.33 | 5.77 | -0.37 | -1.94 | 0.12 | -0.03 | -0.15 | 2.05 | -0.64 | 0.66 |
| Diluted Eps Before Extraordinary Items | -0.33 | 5.77 | -0.37 | -1.94 | 0.12 | -0.03 | -0.15 | 2.05 | -0.64 | 0.66 |
CONSOLIDATED ANNUAL RESULT FOR JUBILANT PHARMOVA LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 61301.6 | 62817.3 | 67029 |
| Total Income | 61414.5 | 63200.6 | 67716 |
| Total Expenditure | 49738.3 | 55054.8 | 58021 |
| Other Income | 112.9 | 383.3 | 687 |
| Operating Profit | 11676.2 | 8145.8 | 9695 |
| Interest | 1454.9 | 1882 | 2723 |
| Exceptional Items | -568.2 | -1689 | |
| PBDT | 10221.3 | 5695.6 | 5283 |
| Depreciation | 3817 | 5540.3 | 3819 |
| Profit Before Tax | 6404.3 | 155.3 | 1464 |
| Tax | 2174.3 | 926.6 | 978 |
| Profit After Tax | 4230 | -771.3 | 486 |
| Net Profit | 4230 | -771.3 | 486 |
| Equity Capital | 159.2 | 159.1 | 158 |
| Face Value (IN RS) | 1 | 1 | 1 |
| Reserves | 53026.4 | 53833.7 | 54181 |
| Calculated EPS | 26 | -3.83 | 4.88 |
| Diluted Eps After Extraordinary Items | 26 | -3.83 | 4.86 |
| Diluted Eps Before Extraordinary Items | 26 | -3.83 | 4.86 |
STANDALONE ANNUAL RESULT FOR JUBILANT PHARMOVA LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 877.5 | 8101.2 | 7847 |
| Total Income | 2136.2 | 9480.1 | 8881 |
| Total Expenditure | 945.3 | 8069 | 7682 |
| Other Income | 1258.7 | 1378.9 | 1034 |
| Operating Profit | 1190.9 | 1411.1 | 1199 |
| Interest | 305.9 | 185.2 | 299 |
| PBDT | 885 | 1225.9 | 900 |
| Depreciation | 62.5 | 432.5 | 483 |
| Profit Before Tax | 822.5 | 793.4 | 417 |
| Tax | 37.5 | 294.6 | 101 |
| Profit After Tax | 785 | 498.8 | 316 |
| Net Profit | 785 | 498.8 | 316 |
| Equity Capital | 159.3 | 159.3 | 159 |
| Face Value (IN RS) | 1 | 1 | 1 |
| Reserves | 12658.9 | 23986.2 | 23586 |
| Calculated EPS | 4.93 | 3.13 | 1.99 |
| Diluted Eps After Extraordinary Items | 4.93 | 3.13 | 1.99 |
| Diluted Eps Before Extraordinary Items | 4.93 | 3.13 | 1.99 |
CONSOLIDATED PROFIT / LOSS FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 8905.51 Cr | 6130.16 Cr | 6281.73 Cr | 6702.9 Cr |
| Sales | 7108.19 Cr | 4291.99 Cr | 4519.4 Cr | 5043.6 Cr |
| Processing Charges / Service Income | 1662.67 Cr | 1767.18 Cr | 1699.9 Cr | 1601.2 Cr |
| Net Sales | 8905.51 Cr | 6130.16 Cr | 6281.73 Cr | 6702.9 Cr |
| Increase/Decrease in Stock | 78.62 Cr | -62.32 Cr | -40.7 Cr | 78.2 Cr |
| Raw Material Consumed | 2923.87 Cr | 1550.33 Cr | 1918.64 Cr | 2062.5 Cr |
| Opening Raw Materials | 578.23 Cr | 347.35 Cr | 364.1 Cr | 432.6 Cr |
| Purchases Raw Materials | 1117.88 Cr | 1365.45 Cr | 1734.93 Cr | 1813.3 Cr |
| Closing Raw Materials | 347.35 Cr | 364.1 Cr | 432.62 Cr | 424.6 Cr |
| Other Direct Purchases / Brought in cost | 251.06 Cr | 201.62 Cr | 252.22 Cr | 241.2 Cr |
| Power & Fuel Cost | 105.79 Cr | 134.3 Cr | 166.71 Cr | 148.9 Cr |
| Electricity & Power | 105.79 Cr | 134.3 Cr | 166.71 Cr | 148.9 Cr |
| Employee Cost | 2172.83 Cr | 2043.39 Cr | 2166.02 Cr | 2216 Cr |
| Salaries, Wages & Bonus | 1865.63 Cr | 1705.07 Cr | 1807.02 Cr | 1867.4 Cr |
| Contributions to EPF & Pension Funds | 154.36 Cr | 163.95 Cr | 178.73 Cr | 181.2 Cr |
| Workmen and Staff Welfare Expenses | 152.59 Cr | 173.25 Cr | 176.62 Cr | 158.9 Cr |
| Other Manufacturing Expenses | 449.4 Cr | 562.32 Cr | 581.13 Cr | 523.2 Cr |
| Processing Charges | 70.58 Cr | 95 Cr | 20.33 Cr | 14 Cr |
| Repairs and Maintenance | 152.56 Cr | 158.68 Cr | 203.75 Cr | 210.6 Cr |
| General and Administration Expenses | 387.92 Cr | 432.34 Cr | 464.06 Cr | 475 Cr |
| Rent , Rates & Taxes | 72.46 Cr | 80.07 Cr | 94.6 Cr | 110 Cr |
| Insurance | 45.93 Cr | 44.27 Cr | 43.14 Cr | 45.2 Cr |
| Printing and stationery | 10.04 Cr | 10.68 Cr | 11.39 Cr | 10.7 Cr |
| Professional and legal fees | 162.87 Cr | 182.17 Cr | 158.15 Cr | 159.2 Cr |
| Traveling and conveyance | 16.04 Cr | 37.18 Cr | 60.41 Cr | 63.6 Cr |
| Selling and Distribution Expenses | 177.15 Cr | 209.71 Cr | 161.6 Cr | 214.3 Cr |
| Advertisement & Sales Promotion | 16.18 Cr | 25.98 Cr | 41.3 Cr | 66.4 Cr |
| Sales Commissions & Incentives | 34.83 Cr | 34.64 Cr | 39.39 Cr | 36.4 Cr |
| Freight and Forwarding | 98.05 Cr | 95.3 Cr | 71.96 Cr | 61 Cr |
| Miscellaneous Expenses | 718.85 Cr | 103.77 Cr | 88.03 Cr | 84 Cr |
| Bad debts /advances written off | 4.76 Cr | 0 | 0 | 0 |
| Loss on disposal of fixed assets(net) | 6.69 Cr | 3.37 Cr | 2.66 Cr | 0 |
| Loss on foreign exchange fluctuations | 64.47 Cr | 46.45 Cr | 0 | 4.2 Cr |
| Loss on sale of non-trade current investments | 0 | 0 | 4.95 Cr | 0 |
| Total Expenditure | 7014.42 Cr | 4973.83 Cr | 5505.49 Cr | 5802.1 Cr |
| Other Income | 29.84 Cr | 11.29 Cr | 38.33 Cr | 68.7 Cr |
| Interest Received | 8.1 Cr | 2.45 Cr | 9.83 Cr | 26.1 Cr |
| Foreign Exchange Gains | 0 | 0 | 17.22 Cr | 0 |
| Operating Profit | 1920.93 Cr | 1167.62 Cr | 814.57 Cr | 969.5 Cr |
| Interest | 247.29 Cr | 145.49 Cr | 188.2 Cr | 272.3 Cr |
| Bank Charges etc | 10.74 Cr | 7.24 Cr | 19.6 Cr | 15.9 Cr |
| PBDT | 1673.64 Cr | 1022.13 Cr | 626.37 Cr | 697.2 Cr |
| Depreciation | 451.65 Cr | 381.7 Cr | 554.03 Cr | 381.9 Cr |
| Profit Before Taxation & Exceptional Items | 1221.99 Cr | 640.43 Cr | 72.34 Cr | 315.3 Cr |
| Exceptional Income / Expenses | -21.23 Cr | 0 | -56.82 Cr | -168.9 Cr |
| Profit Before Tax | 1200.76 Cr | 640.43 Cr | 27.78 Cr | 170.5 Cr |
| Provision for Tax | 376.4 Cr | 217.43 Cr | 92.66 Cr | 97.8 Cr |
| Current Income Tax | 317.95 Cr | 180.55 Cr | 188.8 Cr | 200.3 Cr |
| Deferred Tax | 56.84 Cr | 30.54 Cr | -99.76 Cr | -102.9 Cr |
| Profit After Tax | 824.36 Cr | 423 Cr | -64.88 Cr | 72.7 Cr |
| Minority Interest | 25.8 Lk | 92 Lk | 3.9 Cr | 4.4 Cr |
| Share of Associate | 11.25 Cr | -9.98 Cr | 0 | 0 |
| Consolidated Net Profit | 835.87 Cr | 413.94 Cr | -60.98 Cr | 77.1 Cr |
| Profit Balance B/F | 3844.82 Cr | 4317.71 Cr | 4685.02 Cr | 4536.8 Cr |
| Appropriations | 4680.69 Cr | 4731.65 Cr | 4624.04 Cr | 4613.9 Cr |
| Other Appropriation | 362.81 Cr | 46.63 Cr | 87.31 Cr | 74.2 Cr |
| Equity Dividend % | 500 | 500 | 500 | 500 |
| Earnings Per Share | 52.51 | 26.01 | -3.83 | 4.88 |
| Adjusted EPS | 52.51 | 26.01 | -3.83 | 4.88 |
STANDALONE PROFIT / LOSS FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 2709.5 Cr | 87.75 Cr | 810.12 Cr | 784.7 Cr |
| Sales | 2687.45 Cr | 0 | 685.62 Cr | 638.4 Cr |
| Processing Charges / Service Income | 62.4 Lk | 87.75 Cr | 88.8 Cr | 116.8 Cr |
| Net Sales | 2709.5 Cr | 87.75 Cr | 810.12 Cr | 784.7 Cr |
| Increase/Decrease in Stock | 55.21 Cr | 0 | 3.45 Cr | 39 Cr |
| Raw Material Consumed | 1395.15 Cr | 0 | 411.1 Cr | 316.5 Cr |
| Opening Raw Materials | 248.62 Cr | 0 | 97.16 Cr | 92.5 Cr |
| Purchases Raw Materials | 1080.3 Cr | 0 | 391.73 Cr | 290 Cr |
| Closing Raw Materials | 0 | 0 | 92.6 Cr | 72.5 Cr |
| Other Direct Purchases / Brought in cost | 66.23 Cr | 0 | 14.8 Cr | 6.5 Cr |
| Power & Fuel Cost | 280.4 Cr | 9.27 Cr | 75.37 Cr | 68.4 Cr |
| Electricity & Power | 280.4 Cr | 9.27 Cr | 75.37 Cr | 68.4 Cr |
| Employee Cost | 220.67 Cr | 49.21 Cr | 167.27 Cr | 190 Cr |
| Salaries, Wages & Bonus | 199.31 Cr | 45.75 Cr | 147.02 Cr | 168.9 Cr |
| Contributions to EPF & Pension Funds | 10.36 Cr | 1.82 Cr | 6.99 Cr | 7.6 Cr |
| Workmen and Staff Welfare Expenses | 11 Cr | 1.14 Cr | 12.29 Cr | 11.8 Cr |
| Other Manufacturing Expenses | 218.14 Cr | 1.14 Cr | 49.59 Cr | 60.3 Cr |
| Processing Charges | 15.68 Cr | 0 | 85.1 Lk | 90 Lk |
| Repairs and Maintenance | 87.57 Cr | 91.2 Lk | 23.33 Cr | 35.9 Cr |
| General and Administration Expenses | 44.02 Cr | 25.6 Cr | 80.49 Cr | 76.7 Cr |
| Rent , Rates & Taxes | 7.92 Cr | 51.8 Lk | 2.64 Cr | 1.8 Cr |
| Insurance | 8.9 Cr | 67.8 Lk | 4.88 Cr | 5.3 Cr |
| Printing and stationery | 71 Lk | 15.8 Lk | 93.4 Lk | 60 Lk |
| Professional and legal fees | 7.36 Cr | 9.9 Cr | 49.66 Cr | 46.3 Cr |
| Traveling and conveyance | 3.37 Cr | 6.55 Cr | 10.08 Cr | 9.7 Cr |
| Selling and Distribution Expenses | 53.06 Cr | 33.1 Lk | 9.64 Cr | 9.2 Cr |
| Advertisement & Sales Promotion | 25.9 Lk | 33.1 Lk | 1.43 Cr | 3 Cr |
| Sales Commissions & Incentives | 2.47 Cr | 0 | 6.28 Cr | 4.9 Cr |
| Freight and Forwarding | 49.81 Cr | 0 | 1.93 Cr | 1.3 Cr |
| Miscellaneous Expenses | 15.78 Cr | 8.98 Cr | 9.98 Cr | 8.1 Cr |
| Bad debts /advances written off | 88.9 Lk | 0 | 0 | 0 |
| Loss on disposal of fixed assets(net) | 23.6 Lk | 0 | 0 | 1 Cr |
| Loss on foreign exchange fluctuations | 0 | 1.02 Cr | 0 | 30 Lk |
| Total Expenditure | 2282.44 Cr | 94.54 Cr | 806.89 Cr | 768.2 Cr |
| Other Income | 47.88 Cr | 125.87 Cr | 137.89 Cr | 103.4 Cr |
| Interest Received | 5.7 Cr | 85.7 Lk | 52.7 Lk | 50 Lk |
| Dividend Received | 0 | 97.11 Cr | 97.42 Cr | 33.4 Cr |
| Profit on sale of Fixed Assets | 0 | 1.5 Lk | 42.4 Lk | 0 |
| Foreign Exchange Gains | 0 | 0 | 69 Lk | 0 |
| Operating Profit | 474.94 Cr | 119.08 Cr | 141.12 Cr | 119.9 Cr |
| Interest | 101.8 Cr | 30.58 Cr | 18.52 Cr | 29.9 Cr |
| Bank Charges etc | 3.96 Cr | 0 | 18.9 Lk | 10 Lk |
| PBDT | 373.14 Cr | 88.5 Cr | 122.59 Cr | 90 Cr |
| Depreciation | 99.97 Cr | 6.25 Cr | 43.25 Cr | 48.3 Cr |
| Profit Before Taxation & Exceptional Items | 273.17 Cr | 82.25 Cr | 79.34 Cr | 41.7 Cr |
| Profit Before Tax | 273.17 Cr | 82.25 Cr | 79.34 Cr | 41.7 Cr |
| Provision for Tax | 58.69 Cr | 3.74 Cr | 29.46 Cr | 10.1 Cr |
| Current Income Tax | 48.6 Cr | 14.4 Cr | 13.71 Cr | 6.8 Cr |
| Deferred Tax | 14.46 Cr | -9.77 Cr | 13.77 Cr | 2.3 Cr |
| Profit After Tax | 214.48 Cr | 78.5 Cr | 49.88 Cr | 31.6 Cr |
| Consolidated Net Profit | 214.48 Cr | 78.5 Cr | 49.88 Cr | 31.6 Cr |
| Profit Balance B/F | 1153.26 Cr | 1154.92 Cr | 1154.03 Cr | 1123.6 Cr |
| Appropriations | 1367.74 Cr | 1233.42 Cr | 1203.91 Cr | 1155.2 Cr |
| Other Appropriation | 212.82 Cr | 79.39 Cr | 80.28 Cr | 79.6 Cr |
| Equity Dividend % | 500 | 500 | 500 | 500 |
| Earnings Per Share | 13.47 | 4.93 | 3.13 | 1.99 |
| Adjusted EPS | 13.47 | 4.93 | 3.13 | 1.99 |
CONSOLIDATED CASH FLOW FOR JUBILANT PHARMOVA LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 1212.01 Cr | 630.45 Cr | 27.78 Cr | 170.5 Cr |
| Adjustment | 716.48 Cr | 579.47 Cr | 782.88 Cr | 755.4 Cr |
| Changes In working Capital | 249.9 Cr | -178.29 Cr | 54.31 Cr | 253.1 Cr |
| Cash Flow after changes in Working Capital | 2178.38 Cr | 1031.63 Cr | 864.97 Cr | 1179 Cr |
| Cash Flow from Operating Activities | 1784.27 Cr | 837.54 Cr | 660.67 Cr | 971.3 Cr |
| Cash Flow from Investing Activities | -739.01 Cr | -380.37 Cr | -544.41 Cr | -607.9 Cr |
| Cash Flow from Financing Activitie | -1709.39 Cr | -32.6 Cr | -156.68 Cr | -432.5 Cr |
| Net Cash Inflow / Outflow | -664.14 Cr | 424.57 Cr | -40.43 Cr | -69.1 Cr |
| Opening Cash & Cash Equivalents | 1230.81 Cr | 501.96 Cr | 983.82 Cr | 1013.9 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | -76.98 Cr | 0 | 0 | 0 |
| Effect of Foreign Exchange Fluctuations | 12.26 Cr | 57.29 Cr | 70.53 Cr | 11.6 Cr |
| Closing Cash & Cash Equivalent | 501.96 Cr | 983.82 Cr | 1013.92 Cr | 956.4 Cr |
STANDALONE CASH FLOW FOR JUBILANT PHARMOVA LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 273.17 Cr | 82.25 Cr | 79.34 Cr | 41.7 Cr |
| Adjustment | 196.45 Cr | -60.64 Cr | -35.19 Cr | 48.2 Cr |
| Changes In working Capital | 181.36 Cr | -5.78 Cr | -91.82 Cr | 65.5 Cr |
| Cash Flow after changes in Working Capital | 650.98 Cr | 15.83 Cr | -47.67 Cr | 155.4 Cr |
| Cash Flow from Operating Activities | 608.38 Cr | -3.55 Cr | -65.12 Cr | 143.2 Cr |
| Cash Flow from Investing Activities | 177.96 Cr | 93.1 Cr | 31.07 Cr | -40.3 Cr |
| Cash Flow from Financing Activitie | -781.64 Cr | -107.37 Cr | 22.51 Cr | -77.8 Cr |
| Net Cash Inflow / Outflow | 4.69 Cr | -17.82 Cr | -11.53 Cr | 25.1 Cr |
| Opening Cash & Cash Equivalents | 96.7 Cr | 40.33 Cr | 22.52 Cr | 11 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | -61.06 Cr | 0 | 0 | 0 |
| Closing Cash & Cash Equivalent | 40.33 Cr | 22.5 Cr | 10.99 Cr | 36.1 Cr |
CONSOLIDATED BALANCE SHEET FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 15.92 Cr | 15.92 Cr | 15.91 Cr | 15.8 Cr |
| Equity - Authorised | 143.02 Cr | 143.02 Cr | 143.02 Cr | 143 Cr |
| Equity - Issued | 15.93 Cr | 15.93 Cr | 15.93 Cr | 15.9 Cr |
| Equity Paid Up | 15.92 Cr | 15.92 Cr | 15.91 Cr | 15.8 Cr |
| Equity Shares Forfeited | 20,000 | 20,000 | 20,000 | 0 |
| Face Value | 1 | 1 | 1 | 1 |
| Total Reserves | 4724.75 Cr | 5298.98 Cr | 5377.18 Cr | 5403.6 Cr |
| Capital Reserves | 6.13 Cr | 6.13 Cr | 2.17 Cr | -25.2 Cr |
| Profit & Loss Account Balance | 4317.71 Cr | 4685.02 Cr | 4536.73 Cr | 4539.7 Cr |
| Reserve excluding Revaluation Reserve | 4724.75 Cr | 5298.98 Cr | 5377.18 Cr | 5403.6 Cr |
| Shareholder's Funds | 4741.49 Cr | 5318.56 Cr | 5399.28 Cr | 5433.9 Cr |
| Minority Interest | 3.1 Lk | -2.16 Cr | -7.49 Cr | -12.8 Cr |
| Secured Loans | 20.78 Cr | 200.94 Cr | 265.04 Cr | 299.3 Cr |
| Term Loans - Banks | 20.78 Cr | 600.31 Cr | 306.51 Cr | 157.2 Cr |
| Term Loans - Institutions | 0 | 0 | 0 | 142.1 Cr |
| Unsecured Loans | 2543.19 Cr | 2263.3 Cr | 2845.32 Cr | 2867.8 Cr |
| Long Term Loan in Foreign Currency | 1093.82 Cr | 756.46 Cr | 2845.32 Cr | 2867.8 Cr |
| Deferred Tax Assets / Liabilities | 92.59 Cr | 141.69 Cr | 78.77 Cr | -21.9 Cr |
| Deferred Tax Assets | 500.96 Cr | 424.79 Cr | 537.57 Cr | 600.8 Cr |
| Deferred Tax Liability | 593.55 Cr | 566.48 Cr | 616.34 Cr | 578.9 Cr |
| Other Long Term Liabilities | 222.48 Cr | 219.99 Cr | 483.64 Cr | 760.4 Cr |
| Long Term Provisions | 94.01 Cr | 95.67 Cr | 92.25 Cr | 100.1 Cr |
| Total Non-Current Liabilities | 2973.05 Cr | 2921.59 Cr | 3765.02 Cr | 4005.7 Cr |
| Trade Payables | 520.48 Cr | 567.74 Cr | 821.32 Cr | 856.3 Cr |
| Sundry Creditors | 520.48 Cr | 567.74 Cr | 821.32 Cr | 856.3 Cr |
| Other Current Liabilities | 371.73 Cr | 838.52 Cr | 552.1 Cr | 732.8 Cr |
| Advances received from customers | 0 | 0 | 71.07 Cr | 86.5 Cr |
| Interest Accrued But Not Due | 11.36 Cr | 13.09 Cr | 5.66 Cr | 24.5 Cr |
| Short Term Borrowings | 20 Cr | 64 Cr | 258.26 Cr | 196.5 Cr |
| Secured ST Loans repayable on Demands | 20 Cr | 64 Cr | 258.26 Cr | 196.5 Cr |
| Working Capital Loans- Sec | 20 Cr | 64 Cr | 258.26 Cr | 196.5 Cr |
| Short Term Provisions | 136.62 Cr | 121.34 Cr | 140.73 Cr | 103.4 Cr |
| Provision for Tax | 46.81 Cr | 34.51 Cr | 62.38 Cr | 37 Cr |
| Provision for post retirement benefits | 59.36 Cr | 57.25 Cr | 0 | 0 |
| Total Current Liabilities | 1048.83 Cr | 1591.6 Cr | 1772.4 Cr | 1889 Cr |
| Total Liabilities | 8763.4 Cr | 9829.6 Cr | 10929.2 Cr | 11315.8 Cr |
| Gross Block | 6089.57 Cr | 6691.97 Cr | 7431.77 Cr | 7868.9 Cr |
| Less: Accumulated Depreciation | 1480.82 Cr | 1821.36 Cr | 2248.51 Cr | 2777.7 Cr |
| Net Block | 4608.75 Cr | 4870.61 Cr | 5183.26 Cr | 5091.2 Cr |
| Capital Work in Progress | 277.78 Cr | 291.83 Cr | 773.25 Cr | 1252.3 Cr |
| Non Current Investments | 240.96 Cr | 238.6 Cr | 256.42 Cr | 42.2 Cr |
| Long Term Investment | 240.96 Cr | 238.6 Cr | 256.42 Cr | 42.2 Cr |
| Unquoted | 240.96 Cr | 238.6 Cr | 256.42 Cr | 42.2 Cr |
| Long Term Loans & Advances | 62.84 Cr | 117.64 Cr | 161.55 Cr | 191.9 Cr |
| Other Non Current Assets | 1.35 Cr | 3.98 Cr | 4.09 Cr | 11.3 Cr |
| Total Non-Current Assets | 5810.9 Cr | 6320.4 Cr | 7166.8 Cr | 7439.7 Cr |
| Unquoted | 240.96 Cr | 238.6 Cr | 256.42 Cr | 42.2 Cr |
| Inventories | 1129.38 Cr | 1254.87 Cr | 1380.53 Cr | 1289.6 Cr |
| Raw Materials | 347.35 Cr | 364.1 Cr | 432.62 Cr | 424.6 Cr |
| Work-in Progress | 347.22 Cr | 379.26 Cr | 453.45 Cr | 350 Cr |
| Finished Goods | 242.99 Cr | 252.5 Cr | 241.78 Cr | 264.1 Cr |
| Stores and Spare | 133.78 Cr | 156.25 Cr | 177.1 Cr | 174 Cr |
| Sundry Debtors | 819.9 Cr | 927.99 Cr | 961.24 Cr | 915.9 Cr |
| Debtors more than Six months | 0 | 45.8 Cr | 112.08 Cr | 113.9 Cr |
| Debtors Others | 841.88 Cr | 908.07 Cr | 899.68 Cr | 868.8 Cr |
| Cash and Bank | 671.32 Cr | 984.24 Cr | 1014.3 Cr | 956.8 Cr |
| Cash in hand | 6.5 Lk | 3.9 Lk | 3.3 Lk | 0 |
| Balances at Bank | 662.14 Cr | 979.14 Cr | 1011.06 Cr | 955.6 Cr |
| Other Current Assets | 242.37 Cr | 241.56 Cr | 135.05 Cr | 241.9 Cr |
| Interest accrued and or due on loans | 1.12 Cr | 1.1 Cr | 66.8 Lk | 90 Lk |
| Prepaid Expenses | 82.37 Cr | 83.35 Cr | 89.98 Cr | 91 Cr |
| Short Term Loans and Advances | 89.53 Cr | 100.53 Cr | 271.28 Cr | 228 Cr |
| Advances recoverable in cash or in kind | 64.49 Cr | 98.94 Cr | 137.48 Cr | 115 Cr |
| Advance income tax and TDS | 23.61 Cr | 18.4 Lk | 11.54 Cr | 16.7 Cr |
| Total Current Assets | 2952.5 Cr | 3509.19 Cr | 3762.4 Cr | 3632.2 Cr |
| Net Current Assets (Including Current Investments) | 1903.67 Cr | 1917.59 Cr | 1990 Cr | 1743.2 Cr |
| Total Assets | 8763.4 Cr | 9829.6 Cr | 10929.2 Cr | 11315.8 Cr |
| Contingent Liabilities | 404.11 Cr | 420.31 Cr | 420.89 Cr | 456.2 Cr |
| Total Debt | 2583.97 Cr | 2927.62 Cr | 3410.08 Cr | 3414.1 Cr |
| Book Value | 297.84 | 333.91 | 0 | 343 |
| Adjusted Book Value | 297.84 | 333.91 | 339.04 | 343 |
STANDALONE BALANCE SHEET FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 15.93 Cr | 15.93 Cr | 15.93 Cr | 15.9 Cr |
| Equity - Authorised | 143.02 Cr | 143.02 Cr | 143.02 Cr | 143 Cr |
| Equity - Issued | 15.93 Cr | 15.93 Cr | 15.93 Cr | 15.9 Cr |
| Equity Paid Up | 15.93 Cr | 15.93 Cr | 15.93 Cr | 15.9 Cr |
| Equity Shares Forfeited | 20,000 | 20,000 | 20,000 | 0 |
| Face Value | 1 | 1 | 1 | 1 |
| Total Reserves | 1266.52 Cr | 1265.39 Cr | 2394.77 Cr | 2346.4 Cr |
| Capital Reserves | 108.82 Cr | 108.82 Cr | 1266.51 Cr | 1266.5 Cr |
| Profit & Loss Account Balance | 1154.92 Cr | 1154.03 Cr | 1123.63 Cr | 1075.6 Cr |
| Reserve excluding Revaluation Reserve | 1266.52 Cr | 1265.39 Cr | 2394.77 Cr | 2346.4 Cr |
| Shareholder's Funds | 1282.45 Cr | 1281.82 Cr | 2414.55 Cr | 2374.5 Cr |
| Secured Loans | 95 Cr | 95 Cr | 95 Cr | 167.5 Cr |
| Non Convertible Debentures | 95 Cr | 95 Cr | 95 Cr | 70 Cr |
| Term Loans - Banks | 0 | 0 | 0 | 47.5 Cr |
| Term Loans - Institutions | 0 | 0 | 0 | 50 Cr |
| Unsecured Loans | 325 Cr | 404 Cr | 79 Cr | 79 Cr |
| Loans and advances from subsidiaries | 325 Cr | 404 Cr | 79 Cr | 79 Cr |
| Deferred Tax Assets / Liabilities | 8.86 Cr | 20,000 | -17.03 Cr | -11.9 Cr |
| Deferred Tax Assets | 6.1 Cr | 19.73 Cr | 128.64 Cr | 126.4 Cr |
| Deferred Tax Liability | 14.96 Cr | 19.74 Cr | 111.61 Cr | 114.5 Cr |
| Other Long Term Liabilities | 7.81 Cr | 5.81 Cr | 35.9 Cr | 28.7 Cr |
| Long Term Provisions | 5.34 Cr | 5.16 Cr | 22.82 Cr | 26.8 Cr |
| Total Non-Current Liabilities | 442 Cr | 509.97 Cr | 215.7 Cr | 290.1 Cr |
| Trade Payables | 15.9 Cr | 8.87 Cr | 164.27 Cr | 148.4 Cr |
| Sundry Creditors | 15.9 Cr | 8.87 Cr | 164.27 Cr | 148.4 Cr |
| Other Current Liabilities | 19.95 Cr | 20.8 Cr | 58.24 Cr | 66 Cr |
| Advances received from customers | 0 | 0 | 13.75 Cr | 20.8 Cr |
| Interest Accrued But Not Due | 2.42 Cr | 2.68 Cr | 1.36 Cr | 1.7 Cr |
| Short Term Borrowings | 73 Cr | 0 | 127.5 Cr | 93.9 Cr |
| Secured ST Loans repayable on Demands | 0 | 0 | 127.5 Cr | 93.9 Cr |
| Working Capital Loans- Sec | 0 | 0 | 127.5 Cr | 93.9 Cr |
| Short Term Provisions | 11.3 Cr | 8.01 Cr | 11.18 Cr | 7.1 Cr |
| Provision for Tax | 3.34 Cr | 11.2 Lk | 16.4 Lk | 20 Lk |
| Provision for post retirement benefits | 7.96 Cr | 7.9 Cr | 0 | 0 |
| Total Current Liabilities | 120.15 Cr | 37.68 Cr | 361.19 Cr | 315.4 Cr |
| Total Liabilities | 1844.59 Cr | 1829.47 Cr | 2991.44 Cr | 2980 Cr |
| Gross Block | 148.94 Cr | 148.22 Cr | 956.04 Cr | 1008.5 Cr |
| Less: Accumulated Depreciation | 21.86 Cr | 24.68 Cr | 268.64 Cr | 297.2 Cr |
| Net Block | 127.08 Cr | 123.54 Cr | 687.4 Cr | 711.3 Cr |
| Capital Work in Progress | 32.7 Lk | 6 Lk | 46.97 Cr | 37 Cr |
| Non Current Investments | 1645.98 Cr | 1645.75 Cr | 1656.57 Cr | 1656.9 Cr |
| Long Term Investment | 1645.98 Cr | 1645.75 Cr | 1656.57 Cr | 1656.9 Cr |
| Unquoted | 1645.98 Cr | 1645.75 Cr | 1656.57 Cr | 1656.9 Cr |
| Long Term Loans & Advances | 4.96 Cr | 9.3 Cr | 18.59 Cr | 24.3 Cr |
| Other Non Current Assets | 0 | 2.92 Cr | 3.04 Cr | 9.9 Cr |
| Total Non-Current Assets | 1778.35 Cr | 1781.57 Cr | 2412.56 Cr | 2439.4 Cr |
| Unquoted | 1645.98 Cr | 1645.75 Cr | 1656.57 Cr | 1656.9 Cr |
| Inventories | 0 | 0 | 313.6 Cr | 250.9 Cr |
| Raw Materials | 0 | 0 | 92.6 Cr | 72.5 Cr |
| Work-in Progress | 0 | 0 | 161.97 Cr | 131.4 Cr |
| Finished Goods | 0 | 0 | 27.95 Cr | 20.3 Cr |
| Stores and Spare | 0 | 0 | 21.31 Cr | 22.5 Cr |
| Sundry Debtors | 0 | 21.23 Cr | 188.52 Cr | 194.2 Cr |
| Debtors more than Six months | 0 | 5.2 Lk | 30.89 Cr | 32.3 Cr |
| Debtors Others | 0 | 21.18 Cr | 158.98 Cr | 162.8 Cr |
| Cash and Bank | 40.33 Cr | 22.5 Cr | 10.99 Cr | 36.1 Cr |
| Balances at Bank | 36.24 Cr | 22.5 Cr | 10.99 Cr | 36.1 Cr |
| Other Current Assets | 25.92 Cr | 4.08 Cr | 22.57 Cr | 20.6 Cr |
| Interest accrued and or due on loans | 2.4 Lk | 90,000 | 0 | 0 |
| Prepaid Expenses | 9.5 Lk | 1.21 Cr | 8.69 Cr | 10.7 Cr |
| Short Term Loans and Advances | 0 | 8.1 Lk | 43.19 Cr | 38.8 Cr |
| Advances recoverable in cash or in kind | 0 | 8.1 Lk | 9.01 Cr | 3.9 Cr |
| Total Current Assets | 66.25 Cr | 47.9 Cr | 578.88 Cr | 540.6 Cr |
| Net Current Assets (Including Current Investments) | -53.91 Cr | 10.22 Cr | 217.69 Cr | 225.2 Cr |
| Total Assets | 1844.59 Cr | 1829.47 Cr | 2991.44 Cr | 2980 Cr |
| Contingent Liabilities | 68.85 Cr | 68.84 Cr | 70.14 Cr | 77.5 Cr |
| Total Debt | 493 Cr | 499 Cr | 301.5 Cr | 342.9 Cr |
| Book Value | 80.52 | 80.44 | 0 | 148.57 |
| Adjusted Book Value | 80.52 | 80.44 | 151.35 | 148.57 |
FINANCIAL RATIOS (CONSOLIDATED) FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 52.51 | 26.01 | -3.83 | 4.88 |
| CEPS(Rs) | 80.17 | 50.56 | 30.75 | 28.77 |
| DPS(Rs) | 5 | 5 | 5 | 5 |
| Book NAV/Share(Rs) | 297.84 | 333.91 | 339.04 | 343 |
| Tax Rate(%) | 31.35 | 33.95 | 333.54 | 57.36 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 21.24 | 18.86 | 12.36 | 13.44 |
| EBIT Margin(%) | 16.26 | 12.82 | 3.44 | 6.61 |
| Pre Tax Margin(%) | 13.48 | 10.45 | 0.44 | 2.54 |
| PAT Margin (%) | 9.26 | 6.9 | -1.03 | 1.08 |
| Cash Profit Margin (%) | 14.33 | 13.13 | 7.79 | 6.78 |
| Performance Ratios | ||||
| ROA(%) | 7.82 | 4.55 | -0.63 | 0.65 |
| ROE(%) | 15.94 | 8.41 | -1.21 | 1.34 |
| ROCE(%) | 16.49 | 10.09 | 2.53 | 5.02 |
| Asset Turnover(x) | 0.85 | 0.66 | 0.61 | 0.6 |
| Sales/Fixed Asset(x) | 1.27 | 0.96 | 0.89 | 0.88 |
| Working Capital/Sales(x) | 4.68 | 3.2 | 3.16 | 3.85 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.79 | 1.04 | 1.13 | 1.14 |
| Receivable days | 43.3 | 52.04 | 54.89 | 51.11 |
| Inventory Days | 60.96 | 70.98 | 76.57 | 72.7 |
| Payable days | 45.62 | 133.47 | 134.99 | 143.02 |
| Valuation Parameters | ||||
| PER(x) | 12.96 | 14.91 | 0 | 116.5 |
| PCE(x) | 8.49 | 7.67 | 9.07 | 19.76 |
| Price/Book(x) | 2.28 | 1.16 | 0.82 | 1.66 |
| Yield(%) | 0.73 | 1.29 | 1.79 | 0.88 |
| EV/Net Sales(x) | 1.43 | 1.32 | 1.09 | 1.71 |
| EV/Core EBITDA(x) | 6.63 | 6.95 | 8.39 | 11.8 |
| EV/EBIT(x) | 8.8 | 10.33 | 31.65 | 25.83 |
| EV/CE(x) | 1.45 | 0.83 | 0.63 | 1.29 |
| M Cap / Sales | 1.22 | 1.01 | 0.71 | 1.34 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -2.72 | 0.52 | 2.47 | 6.71 |
| Core EBITDA Growth(%) | -3.69 | -17.43 | -30.24 | 19.03 |
| EBIT Growth(%) | -3.33 | -24.72 | -72.17 | 105 |
| PAT Growth(%) | -8.23 | -24.81 | -115.71 | 212.02 |
| EPS Growth(%) | -6.88 | -50.48 | -114.74 | 227.19 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.55 | 0.55 | 0.63 | 0.63 |
| Current Ratio(x) | 2.82 | 2.2 | 2.12 | 1.92 |
| Quick Ratio(x) | 1.74 | 1.42 | 1.34 | 1.24 |
| Interest Cover(x) | 5.86 | 5.4 | 1.15 | 1.63 |
| Total Debt/Mcap(x) | 0.24 | 0.47 | 0.77 | 0.38 |
FINANCIAL RATIOS (STANDALONE) FOR JUBILANT PHARMOVA LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 13.47 | 4.93 | 3.13 | 1.99 |
| CEPS(Rs) | 19.74 | 5.32 | 5.85 | 5.03 |
| DPS(Rs) | 5 | 5 | 5 | 5 |
| Book NAV/Share(Rs) | 80.52 | 80.44 | 151.35 | 148.57 |
| Tax Rate(%) | 21.49 | 4.55 | 37.13 | 24.22 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 15.76 | -7.73 | 0.4 | 2.1 |
| EBIT Margin(%) | 13.84 | 128.59 | 12.08 | 9.12 |
| Pre Tax Margin(%) | 10.08 | 93.73 | 9.79 | 5.31 |
| PAT Margin (%) | 7.92 | 89.46 | 6.16 | 4.03 |
| Cash Profit Margin (%) | 11.61 | 96.59 | 11.5 | 10.18 |
| Performance Ratios | ||||
| ROA(%) | 5.89 | 4.27 | 1.7 | 1.06 |
| ROE(%) | 11.03 | 6.12 | 2.06 | 1.32 |
| ROCE(%) | 11.82 | 6.35 | 3.67 | 2.64 |
| Asset Turnover(x) | 0.74 | 0.05 | 0.28 | 0.26 |
| Sales/Fixed Asset(x) | 2.22 | 0.59 | 0.89 | 0.8 |
| Working Capital/Sales(x) | -50.26 | 8.58 | 3.72 | 3.48 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.45 | 1.69 | 1.13 | 1.25 |
| Receivable days | 0 | 88.33 | 71.91 | 89.01 |
| Inventory Days | 0 | 0 | 143.45 | 131.29 |
| Payable days | 48.38 | 0 | 142.11 | 160.53 |
| Valuation Parameters | ||||
| PER(x) | 50.53 | 78.68 | 89.1 | 286.05 |
| PCE(x) | 34.47 | 72.88 | 47.72 | 113.13 |
| Price/Book(x) | 8.45 | 4.82 | 1.84 | 3.83 |
| Yield(%) | 0.73 | 1.29 | 1.79 | 0.88 |
| EV/Net Sales(x) | 4.17 | 75.82 | 5.85 | 11.91 |
| EV/Core EBITDA(x) | 23.77 | 55.87 | 33.56 | 77.95 |
| EV/EBIT(x) | 30.11 | 58.97 | 48.38 | 130.53 |
| EV/CE(x) | 6.12 | 3.64 | 1.58 | 3.44 |
| M Cap / Sales | 4 | 70.39 | 5.49 | 11.52 |
| Growth Ratio | ||||
| Net Sales Growth(%) | -13.71 | -96.76 | 11.63 | -3.14 |
| Core EBITDA Growth(%) | -12.72 | -74.93 | 6.41 | -14.96 |
| EBIT Growth(%) | -13.81 | -69.91 | 2.26 | -26.79 |
| PAT Growth(%) | -33.21 | -63.4 | -38.03 | -36.67 |
| EPS Growth(%) | -33.21 | -63.4 | -38.03 | -36.67 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.38 | 0.39 | 0.13 | 0.15 |
| Current Ratio(x) | 0.55 | 1.27 | 1.6 | 1.71 |
| Quick Ratio(x) | 0.55 | 1.27 | 0.73 | 0.92 |
| Interest Cover(x) | 3.68 | 3.69 | 5.28 | 2.39 |
| Total Debt/Mcap(x) | 0.05 | 0.08 | 0.07 | 0.04 |
SHARE HOLDING PATTERN FOR JUBILANT PHARMOVA LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 46.51 | 47.39 | 47.39 | 47.39 | 47.39 | 47.39 | 47.39 | 47.39 | 47.39 | 47.39 |
| FII % | 23.47 | 23.06 | 23.38 | 23.22 | 23.20 | 23.20 | 20.29 | 19.06 | 19.50 | 17.94 |
| DII % | 0.58 | 1.21 | 1.22 | 1.22 | 1.22 | 1.22 | 1.39 | 1.50 | 1.81 | 1.96 |
| Public % | 25.24 | 24.67 | 24.33 | 23.24 | 24.50 | 24.48 | 26.14 | 26.49 | 25.77 | 25.73 |
PEER COMPARISON FOR JUBILANT PHARMOVA LIMITED
CORPORATE ACTIONS FOR JUBILANT PHARMOVA
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 17-Oct-2024 | Board Meeting - Quarterly Results | 25-Oct-2024 |
| BSE 10-Jul-2024 | Board Meeting - Quarterly Results | 19-Jul-2024 |
| BSE 29-May-2024 | Dividend - Rs.5.0000 per share(500%)Final Dividend | |
| BSE 22-May-2024 | Board Meeting - Final Dividend & Audited Results | 29-May-2024 |
| BSE 23-Jan-2024 | Board Meeting - Quarterly Results | 02-Feb-2024 |
| BSE 19-Oct-2023 | Board Meeting - Quarterly Results | 27-Oct-2023 |
| BSE 26-Jun-2023 | Board Meeting - Quarterly Results | 19-Jul-2023 |
| BSE 29-May-2023 | Dividend - Rs.5.0000 per share(500%)Final Dividend | |
| BSE 23-May-2023 | Board Meeting - Final Dividend & Audited Results | 29-May-2023 |
| BSE 25-Jan-2023 | Board Meeting - Quarterly Results | 03-Feb-2023 |
| BSE 13-Oct-2022 | Board Meeting - Quarterly Results | 21-Oct-2022 |
| BSE 26-Jul-2022 | Board Meeting - Quarterly Results | 02-Aug-2022 |
| BSE 27-May-2022 | Dividend - Rs.5.0000 per share(500%)Final Dividend | |
| BSE 20-May-2022 | Board Meeting - Final Dividend & Audited Results | 27-May-2022 |
| BSE 04-Apr-2022 | SAST - Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that subject to applicable laws, the Company has entered into Share Purchase Agreement, and Share Subscription and Shareholders Agreement on April 1, 2022 for acquiring equity and preference shares of SPV Laboratories Private Limite... | |
| BSE 27-Jan-2022 | Board Meeting - Quarterly Results | 04-Feb-2022 |
| BSE 14-Oct-2021 | Board Meeting - Quarterly Results | 22-Oct-2021 |
CORPORATE ANNOUNCEMENTS FOR JUBILANT PHARMOVA
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 27-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Copy of Newspaper publication for the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2024 |
| BSE 25-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release along with Earnings Presentation for the quarter and half year ended September 30 2024 |
| BSE 25-Oct-2024 | Outcome FILE | Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30 2024 Approval of Unaudted Financial Results for the quarter and half year ended September 30 2024 |
| BSE 25-Oct-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of The Board Meeting Held On October 25 2024 - Approval Of Unaudited Financial Results For Quarter And Half Year Ended September 30 2024 Outcome of the Board Meeting held on October 25 2024 - Approval of Unaudited Financial Results for quarter and half year ended September 30 2024 |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement - Voluntary Prepayment Of USD 25 Million Term Loan Equivalent To Rs. 210 Cr Voluntary prepayment of USD 25 million term loan equivalent to Rs. 210 cr |
| BSE 19-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Investors/ Analysts Meeting |
| BSE 17-Oct-2024 | Intimation FILE | Board Meeting Intimation for Intimation Of Board Meeting Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Intimation of Board Meeting - To consider the unaudited Financial Results for the Quarter and Half Year ended September 30 2024. |
| BSE 10-Oct-2024 | General Announcements FILE | Deletion Of Tax Deman Raised On Jubilant Generics Ltd - Step Down Susbsidiary Jubilant Generics Limited had preferred rectification application against certain tax demands rasied by the Income Tax Department for Assessment Year 2020-21. Pursuant to rectification orders received tax demand of Rs.38.13 crores stands deleted in its entirety. |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Announcement under Regulation 74(5) of SEBI (DP) Regulations 2018 |
| BSE 04-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Updates on Acquisition Further to our letter dated AUgust 16 2024 we enclose disclosure on Out Option Agreement |
| BSE 01-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Announcement under Regulation 30 - Appointment of Senior Management Personnel |
| BSE 01-Oct-2024 | General Announcements FILE | Announcement Under Regulation 30 Announcement under Regulation 30 |
| BSE 30-Sep-2024 | Intimation FILE | Closure of Trading Window Announcement for Closure of Trading Window. |
| BSE 28-Sep-2024 | General Announcements FILE | Communication From USFDA Communication from USFDA |
| BSE 26-Sep-2024 | General Announcements FILE | Communication From USFDA. Communication from USFDA |
| BSE 20-Sep-2024 | General FILE | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for East Bridge Capital Master Fund Ltd & Others |
| BSE 11-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Announcement under Regulation 30- Investors Meeting. |
| BSE 10-Sep-2024 | General Announcements FILE | Announcement Under Regulation 30 - Communication From USFDA Announcement under Regulation 30 - Communication from USFDA |
| BSE 30-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Please find attached Scrutinizers Report and Voting Results for the Annual General Meeting held on August 30 2024 |
| BSE 30-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Please find attached Outcome of Annual General Meeting held on August 30 2024 along with the Voting Results |
| BSE 24-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation for loss of share certificate |
| BSE 23-Aug-2024 | General Announcements FILE | Postal Ballot Results Alongwith Scrutinizers Report Postal Ballot results alongwith scrutinizers report |
| BSE 16-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Investors/ Analysts Meeting on August 22 2024 in Mumbai and August 23 2024 in Pune. |
| BSE 16-Aug-2024 | General Announcements FILE | Jubilant Biosys Limited A Wholly Owned Subsidiary Of The Company Has Signed And Issued A 'Put Option Offer' To Pierre Fabre Laboratories Which Sets Forth An Offer To Acquire 80% Equity Capital (Approx. Euro 4.4 Million Over A Period Of 2 Years) In A New Company To Be Incorporated In France Which New Company Shall Acquire Pierre Fabre'S R&D Centre (Including R&D Site And R&D Activities) At Saint Julien France. Jubilant Biosys Limited a wholly owned subsidiary of the Company has signed and issued a "put option offer" to Pierre Fabre Laboratories. |
| BSE 09-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulation 30 - Newspaper publication |
| BSE 09-Aug-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Annual report for 2023-24 |
| BSE 08-Aug-2024 | Intimation FILE | Notice Of 46Th Annual General Meeting Alongwith The Annual Report For The Financial Year 2023-24 Notice of 46th Annual General Meeting alongwith the Annual Report for the Financial Year 2023-24 |
| BSE 08-Aug-2024 | General Announcements FILE | Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report for the Financial Year 2023-24 |
| BSE 06-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulation 30 - Newspaper Publication |
| BSE 02-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Management Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
INSIDER TRADING FOR JUBILANT PHARMOVA
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 13-Sep-2024 13-Sep-2024 | Sell ESOP | 6,877 @ 0.00 (0.00 %) | Jubilant Employees Welfare Trust |
| BSE 05-Sep-2024 05-Sep-2024 | Sell ESOP | 18,045 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 03-Sep-2024 03-Sep-2024 | Sell ESOP | 39,147 @ 0.00 (0.02 %) | Jubilant Employees Welfare Trust |
| BSE 26-Aug-2024 26-Aug-2024 | Sell ESOP | 1,576 @ 0.00 (0.00 %) | JUBILANT EMPLOYEES WELFARE TRUST |
| BSE 14-Aug-2024 14-Aug-2024 | Sell ESOP | 22,858 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 23-Jun-2023 23-Jun-2023 | Buy Market | 33,673 @ 0.00 (0.03 %) | Jubilant Employees Welfare Trust |
| BSE 23-Jun-2023 23-Jun-2023 | Buy Market | 14,327 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 19-Jun-2023 20-Jun-2023 | Buy Market | 93,346 @ 0.00 (0.06 %) | Jubilant Employees Welfare Trust |
| BSE 19-Jun-2023 20-Jun-2023 | Buy Market | 20,680 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 15-Jun-2023 16-Jun-2023 | Buy Market | 22,434 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 15-Jun-2023 16-Jun-2023 | Buy Market | 95,448 @ 0.00 (0.06 %) | Jubilant Employees Welfare Trust |
| BSE 13-Jun-2023 14-Jun-2023 | Buy Market | 7,251 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 13-Jun-2023 14-Jun-2023 | Buy Market | 62,561 @ 0.00 (0.04 %) | Jubilant Employees Welfare Trust |
| BSE 09-Jun-2023 12-Jun-2023 | Buy Market | 46,619 @ 0.00 (0.03 %) | Jubilant Employees Welfare Trust |
| BSE 09-Jun-2020 12-Jun-2023 | Buy Market | 4,414 @ 0.00 (0.00 %) | Jubilant Employees Welfare Trust |
| BSE 05-Jun-2023 06-Jun-2023 | Buy Market | 103,753 @ 0.00 (0.07 %) | Jubilant Employees Welfare Trust |
| BSE 01-Jun-2023 02-Jun-2023 | Buy Market | 58,210 @ 0.00 (0.03 %) | JUBILANT EMPLOYEES WELFARE TRUST |
| BSE 05-Dec-2022 05-Dec-2022 | Buy Market | 20,112 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 02-Dec-2022 02-Dec-2022 | Buy Market | 8,925 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
| BSE 28-Nov-2022 28-Nov-2022 | Buy Market | 5,252 @ 0.00 (0.00 %) | Jubilant Employees Welfare Trust |
| BSE 25-Nov-2022 25-Nov-2022 | Buy Market | 2,500 @ 0.00 (0.00 %) | Jubilant Employees Welfare Trust |
| BSE 23-Nov-2022 24-Nov-2022 | Buy Market | 50,988 @ 0.00 (0.03 %) | Jubilant Employees Welfare Trust |
| BSE 17-Nov-2022 21-Nov-2022 | Buy Market | 10,209 @ 0.00 (0.00 %) | Jubilant Employees Welfare Trust |
| BSE 22-Nov-2022 22-Nov-2022 | Buy Market | 6,199 @ 0.00 (0.01 %) | Jubilant Employees Welfare Trust |
BULK BLOCK DEALS FOR JUBILANT PHARMOVA LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 15-Jul-2024 | Buy BULK | 1,386,289 @ 718.15 | EAST BRIDGE CAPITAL MASTER FUND I LIMITED |
| BSE 15-Jul-2024 | Sell BULK | 1,392,000 @ 718.15 | EAST BRIDGE CAPITAL MASTER FUND LIMITED |
| BSE 19-Sep-2022 | Sell BLOCK | 683,197 @ 313.30 | ISHARES CORE EMERGING MARKETS MAURITIUS CO |
| BSE 19-Sep-2022 | Buy BLOCK | 683,197 @ 313.30 | ISHARES CORE MSCI EMERGING MARKETS ETF |
| BSE 19-Sep-2022 | Sell BLOCK | 84,898 @ 313.30 | ISHARES INDIA SC MAURITIUS COMPANY |
| BSE 19-Sep-2022 | Buy BLOCK | 84,898 @ 313.30 | ISHARES MSCI INDIA SMALL-CAP ETF |
DIVIDEND BY JUBILANT PHARMOVA LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 02-Aug-2024 | DIVIDEND | 5 |
| 10-Aug-2023 | DIVIDEND | 5 |
| 11-Aug-2022 | DIVIDEND | 5 |
| 05-Aug-2021 | DIVIDEND | 5 |
SPLIT / BONUS BY JUBILANT PHARMOVA LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
